Get the Stockscreener App
1.47
6.37%
-0.10
After Hours:
1.55
0.08
+5.44%
Inmune Bio Inc stock is traded at $1.47, with a volume of 388.03K.
It is down -6.37% in the last 24 hours and up +0.00% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$1.57
Open:
$1.64
24h Volume:
388.03K
Relative Volume:
0.97
Market Cap:
$39.08M
Revenue:
$50,000
Net Income/Loss:
$-49.89M
P/E Ratio:
-0.687
EPS:
-2.1398
Net Cash Flow:
$-31.55M
1W Performance:
+3.52%
1M Performance:
+0.00%
6M Performance:
-39.26%
1Y Performance:
-83.90%
1-Day Range:
$1.44
$1.67
1-Week Range:
$1.44
$1.7386
52-Week Range:
$1.38
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.47 | 41.74M | 50,000 | -49.89M | -31.55M | -2.1398 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
Inmune Bio announces FDA alignment on integrated Phase 2B/3 registration pathway for Xpro1595 in early Alzheimer's disease - marketscreener.com
INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial? - Stocktwits
INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial? - Asianet Newsable
INmune Bio Gains FDA Alignment On Phase 2b/3 Trial Design For Alzheimer's Drug XPro1595 - Nasdaq
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease - The Manila Times
FDA sets path for 1,000-patient early Alzheimer’s trial using immune therapy - Stock Titan
INmune Bio submits pre-submission package for CORDStrom with MHRA - Yahoo Finance
INmune Bio, Inc. (NASDAQ:INMB) Given Average Rating of “Reduce” by Brokerages - Defense World
INmune Bio (INMB) Advances with Regulatory Submission for CORDSt - GuruFocus
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB - The Manila Times
Rare 'butterfly skin' disease therapy takes key step toward UK review - Stock Titan
Death Cross: Whats the profit margin of INmune Bio IncJuly 2025 Gainers & Verified Chart Pattern Signals - baoquankhu1.vn
Smart Money: Will INmune Bio Inc benefit from geopolitical trendsJuly 2025 Trends & Consistent Profit Trading Strategies - baoquankhu1.vn
Retail Surge: What is the earnings history of INmune Bio Inc2025 Valuation Update & Fast Gaining Stock Reports - baoquankhu1.vn
Aug Movers: Will INmune Bio Inc benefit from geopolitical trendsInsider Buying & Expert Approved Momentum Ideas - baoquankhu1.vn
INmune Bio: Undervalued Pipeline with 2026 Clinical and Regulatory Catalysts Driving Buy Rating - TipRanks
INmune Bio outlines 2025 progress on Alzheimer’s and RDEB therapies By Investing.com - Investing.com Australia
New Highs: Can ProShares Trust ProShares UltraShort SmallCap600 expand into new marketsDollar Strength & Reliable Intraday Trade Plans - baoquankhu1.vn
INmune Bio outlines 2026 regulatory path in shareholder letter - TipRanks
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives - TradingView
INmune Bio (INMB) Reflects on Key Progress and Financial Stabili - GuruFocus
INmune Bio (INMB) Reflects on Key Progress and Financial Stability in 2025 - GuruFocus
INmune Bio outlines 2025 progress on Alzheimer’s and RDEB therapies - Investing.com
INmune Bio, Inc. Provides Investor Update on 2025 Progress and Future Regulatory Plans - Quiver Quantitative
ETF Watch: How liquid is Capital Growth Mortgage Investors L P Preferred Security stockJuly 2025 News Drivers & Fast Gain Stock Tips - baoquankhu1.vn
Sell Signal: Will Reading International Inc benefit from geopolitical trends2025 Trading Recap & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Aug Rallies: What is the earnings history of INmune Bio IncMarket Performance Report & Daily Technical Forecast Reports - baoquankhu1.vn
Is INmune Bio Inc. trading at a discountDay Trade & Reliable Price Breakout Alerts - bollywoodhelpline.com
Take Profit: Is Varex Imaging Corporation still a buy after recent gains - baoquankhu1.vn
INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial - MSN
INmune Bio, Inc. (NASDAQ:INMB) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Aug Breakouts: How liquid is INmune Bio Inc. stockJuly 2025 Momentum & Consistent Return Strategy Ideas - baoquankhu1.vn
How INmune Bio Inc stock reacts to bond yieldsQuarterly Market Review & Weekly High Return Opportunities - Bộ Nội Vụ
How interest rate cuts could boost INmune Bio Inc. stockTrail vs Road Selection & lightweight options for faster days - Улправда
Can INmune Bio Inc. stock deliver sustainable ROEBreakout Watch & High Conviction Investment Ideas - Улправда
Risk Recap: How INmune Bio Inc. stock reacts to bond yieldsJuly 2025 Trends & Risk Controlled Swing Trade Alerts - ulpravda.ru
Will INmune Bio Inc. stock outperform Dow Jones indexLayoff News & Expert-Curated Trade Recommendations - ulpravda.ru
Is INmune Bio Inc. stock a top pick in earnings seasonPortfolio Performance Report & Free Daily Entry Point Trade Alerts - ulpravda.ru
How INmune Bio Inc. stock benefits from strong dollar2025 Buyback Activity & Real-Time Buy Zone Alerts - ulpravda.ru
What hedge fund activity signals for INmune Bio Inc. stock2025 Volume Leaders & Safe Capital Growth Stock Tips - ulpravda.ru
Will INmune Bio Inc. stock benefit from automation2025 Market WrapUp & AI Based Trade Execution Alerts - ulpravda.ru
Is INmune Bio Inc. stock a good choice for value investorsTrade Risk Assessment & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
What is the fair value of INmune Bio Inc. stock nowTrade Volume Summary & AI Forecast Swing Trade Picks - ulpravda.ru
INmune Bio reverses early gains after stock offering - MSN
Energy Moves: Can INmune Bio Inc. stock deliver sustainable ROEMarket Risk Summary & Free Safe Capital Growth Stock Tips - Улправда
INmune Bio Inc.Common stock (NQ: INMB - FinancialContent
Is INmune Bio Inc. stock vulnerable to regulatory risksReal-Time Stock Alerts & Boost Wealth With Growth - Улправда
INmune Bio (INMB) price target decreased by 37.50% to 5.36 - MSN
Aug EndMonth: Will INmune Bio Inc stock outperform Dow Jones indexLong Setup & Verified Momentum Watchlists - moha.gov.vn
Can INmune Bio Inc. stock withstand economic slowdownEarnings Revision Updates & Breakout Portfolio Performance - ulpravda.ru
INMUNE BIO INC (INMB) Stock Technical Analysis - Chartmill
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):